Tryfon obtained his B.Sc. in Chemistry from the Aristotle University of Thessaloniki, Greece in 2010 and his M.Sc., summa cum laude, in Synthetic Organic Chemistry in 2012, under the guidance of Prof. J. Stephanidou – Stephanatou at the same University. In 2017 he obtained his Ph.D., cum laude, in Medicinal Chemistry under the guidance of Prof. Alexander Dömling in the Group of Drug Design at the University of Groningen, The Netherlands. His thesis focused on ‘’Innovative Multicomponent Reactions and their Use in Medicinal Chemistry”.
After obtaining his Ph.D., Tryfon joined Syncom B.V. as a medicinal chemist working on an immuno-oncology project in close collaboration with the University of Groningen. Since 2014, he has been a co-founder and CSO of TelesisPharma B.V. in Groningen, a company focusing on exploring novel synthetic routes to APIs using multicomponent reactions. In Dec 2018, he joined Prof. Paul Brennan’s group at the Oxford Drug Discovery Institute at the University of Oxford, UK, as a postdoctoral scientist focusing on Dementia, a project funded by Alzheimer’s Research, UK.
Multicomponent reaction–derived covalent inhibitor space
Sutanto F. et al, (2021), Science Advances, 7
Structure and Reactivity of Glycosyl Isocyanides
Neochoritis CG. et al, (2019), European Journal of Organic Chemistry, 2019, 50 - 55